Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04481724 · ClinicalTrials.gov registry record · NA
Gamma-linolenic Acid Supplementation Study
A NA study, sponsored by Virta Health.
- Completed
- Registry status
- NA
- Development phase
- 302
- Enrollment target
NCT04481724: Completed NA study, sponsored by Virta Health.
NCT04481724 is a NA study that has completed, run by Virta Health. The registered enrollment target is 302 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04481724, a NA study, has completed, sponsored by Virta Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 302 participants
- Enrollment target
Study Summary
Weight regain following weight loss is common. In rodent models of obesity and pilot studies in humans, increasing membrane arachidonic acid content improves fuel partitioning and prevents weight regain. This study aims to understand the effect of gamma-linolenic acid (GLA) supplementation on weight loss maintenance in Virta Health patients.
Primary Outcome
Body weight measured on a calibrated scale. Interim analyses at 12 and 18 months; if greater weight loss is maintained in the GLA compared to placebo group, the study will be unblinded and placebo group participants will cross over to GLA for the remainder of the trial.
Interventions
- DIETARY_SUPPLEMENT placebo
- DIETARY_SUPPLEMENT gamma-linolenic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2020-07-22 |
| Est. Completion | 2023-09-15 |
| Phase | NA |
What the finished NCT04481724 record still lists
NCT04481724 is an interventional study that assigns participants to a tested intervention. The registered 302 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT04481724 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04481724 about?
NCT04481724 is a clinical study titled "Gamma-linolenic Acid Supplementation Study". Weight regain following weight loss is common. In rodent models of obesity and pilot studies in humans, increasing membrane arachidonic acid content improves fuel partitioning and prevents weight regain. This study aims to understand the effect of gamma-linolenic acid (GLA) supplementation on weight...
What is the current status of trial NCT04481724?
This trial is currently completed. It is a NA study. The enrollment target is 302 participants. The study started on 2020-07-22. Estimated completion is 2023-09-15.
What interventions are being tested in trial NCT04481724?
The interventions under investigation include: placebo (DIETARY_SUPPLEMENT), gamma-linolenic acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04481724?
This trial is sponsored by Virta Health, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04481724's enrollment target sits among peer trials
302 330th of 2000 higher than 1,671 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI